This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Haemonetics | |
|---|---|
| Name | Haemonetics |
| Type | Public |
| Industry | Medical devices |
| Founded | 1971 |
| Founder | Dr. Michael Fasman |
| Headquarters | Braintree, Massachusetts, United States |
| Area served | Worldwide |
| Key people | David K. McIntyre |
| Products | Blood management systems, apheresis machines, blood collection systems, blood component management |
| Revenue | (see Financial Performance) |
| Num employees | (see Corporate Structure) |
Haemonetics
Haemonetics is a global medical technology company focused on blood and plasma management systems, apheresis equipment, blood component processing, and hospital transfusion solutions. The company provides products and services to blood centers, plasma collection networks, hospitals, and research institutions across North America, Europe, Asia-Pacific, and Latin America. Its operations intersect with organizations involved in transfusion medicine, biopharmaceutical manufacturing, hospital networks, and public health agencies.
Founded in 1971 by Dr. Michael Fasman and other entrepreneurs, Haemonetics developed early automated blood processing devices used by organizations such as American Red Cross and Mayo Clinic during the 1970s and 1980s. The company expanded internationally through partnerships and distributors linked with entities like NHS Blood and Transplant and Sanquin, and navigated regulatory environments influenced by agencies including Food and Drug Administration and European Medicines Agency. Throughout the 1990s and 2000s Haemonetics pursued growth via acquisitions and strategic alliances with companies in the medtech sector similar to transactions seen with Baxter International and Terumo Corporation; it competed and collaborated within markets alongside firms like Fresenius Kabi, Grifols, Becton Dickinson, and GE Healthcare. Corporate milestones included listings on public exchanges comparable to New York Stock Exchange filings by peer companies and global expansions that connected the firm to logistics networks used by UPS and DHL. Partnerships with academic centers such as Johns Hopkins Hospital, Cleveland Clinic, and Brigham and Women's Hospital supported clinical validation and adoption. The company weathered sector shifts driven by healthcare policy decisions in jurisdictions represented by Centers for Medicare & Medicaid Services and by public health responses exemplified by World Health Organization guidance.
Haemonetics designs a portfolio spanning automated apheresis systems, blood collection sets, processing devices, and software platforms that integrate with hospital information systems like those from Epic Systems and Cerner Corporation. Its apheresis platforms are used alongside consumables and disposables similar to those supplied by Terumo BCT and interface with cold chain logistics used by Pfizer and Moderna in biopharma distribution. Automation and software tools support workflows in blood centers such as New York Blood Center and Canadian Blood Services, and incorporate connectors compatible with laboratory analyzers from Siemens Healthineers and Roche Diagnostics. The product suite addresses component separation, leukoreduction, pathogen reduction compatibility (in contexts involving technologies from Terumo and Cerus Corporation), and inventory management often coordinated with hospital supply chains like those used by HCA Healthcare and Kaiser Permanente. Device design and manufacturing draw on quality systems consistent with standards set by International Organization for Standardization and norms enforced by Occupational Safety and Health Administration in the United States.
Clinical use cases include apheresis for therapeutic indications treated at centers such as Mayo Clinic and Massachusetts General Hospital, autologous and allogeneic blood component collection for transfusion services at institutions like Mount Sinai Health System and UCSF Medical Center, and plasma collection for fractionation performed by companies akin to CSL Behring and Grifols. Markets span hospital transfusion services, community blood centers, plasma collection networks, and biopharmaceutical contract manufacturers that supply biologics to companies including Johnson & Johnson and Baxter. Haemonetics products are deployed in disaster response and mass casualty settings coordinated with agencies like Federal Emergency Management Agency and humanitarian organizations such as Doctors Without Borders.
R&D efforts have been conducted in collaboration with academic and clinical partners including Harvard Medical School, Stanford University School of Medicine, and University of California, San Francisco, and with industry partners in fields related to transfusion medicine like American Association of Blood Banks research initiatives. Innovation areas include automation, digital health integration paralleling work at Philips Healthcare and Siemens Healthineers, point-of-care connectivity, and consumable chemistry optimization informed by collaborations with contract research organizations similar to Charles River Laboratories. The company participates in scientific meetings organized by bodies such as International Society of Blood Transfusion and AABB (formerly American Association of Blood Banks), contributing to studies on component yield, donor safety, and process efficiency alongside investigators from University of Pennsylvania and Imperial College London.
Haemonetics operates corporate and manufacturing sites across regions encompassing North America, Europe, and Asia, interfacing with distributors and service organizations like Medtronic-style global networks and regional partners in markets like China and India. Executive leadership reports to a board of directors drawn from industry peers with ties to firms such as Thermo Fisher Scientific and Boston Scientific. Supply chain operations coordinate with original equipment manufacturers and suppliers using enterprise resource planning systems similar to those used by SAP and Oracle Corporation. Clinical education and sales channels engage key accounts including hospital systems like Ascension and governmental purchasers comparable to Department of Veterans Affairs procurement.
Products are regulated by agencies including Food and Drug Administration 510(k) and PMA processes, notified bodies under the Medical Device Regulation (EU) 2017/745, and national regulators such as Health Canada and Australia’s Therapeutic Goods Administration. Quality management aligns with ISO 13485 standards and safety reporting interacts with pharmacovigilance and device vigilance frameworks akin to processes run by European Commission medical device oversight. Clinical safety evaluations have been conducted in settings monitored by institutional review boards like those at Columbia University Irving Medical Center and overseen by standards promulgated by organizations such as Good Clinical Practice guidance.
Haemonetics’ financial results reflect revenue from products, consumables, services, and recurring contracts in markets influenced by reimbursement policies from entities like Centers for Medicare & Medicaid Services and payer systems employed by UnitedHealth Group and Anthem, Inc.. The company has executed acquisitions and divestitures to augment capabilities in technologies and geographic reach, following patterns seen in transactions by companies such as Danaher Corporation and Stryker Corporation. Investment and shareholder activity involve institutional investors including asset managers similar to BlackRock and Vanguard Group, and public reporting aligns with practices of companies listed on exchanges like the New York Stock Exchange.
Category:Medical device companies